Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post‐brain metastases survival

BACKGROUND: Melanoma patients who develop brain metastases (B‐Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B‐Met development and post‐B–Met survival. ME...

Full description

Saved in:
Bibliographic Details
Published in:Cancer Vol. 117; no. 8; pp. 1711 - 1720
Main Authors: Zakrzewski, Jan, Geraghty, Laurel N., Rose, Amy E., Christos, Paul J., Mazumdar, Madhu, Polsky, David, Shapiro, Richard, Berman, Russell, Darvishian, Farbod, Hernando, Eva, Pavlick, Anna, Osman, Iman
Format: Journal Article
Language:English
Published: Hoboken Wiley Subscription Services, Inc., A Wiley Company 15-04-2011
Wiley-Blackwell
Subjects:
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Abstract BACKGROUND: Melanoma patients who develop brain metastases (B‐Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B‐Met development and post‐B–Met survival. METHODS: A prospectively accrued cohort of 900 melanoma patients was studied to identify clinicopathologic features of primary melanoma (eg, thickness, ulceration, mitotic index, and lymphovascular invasion) that are predictive of B‐Met development and survival after a diagnosis of B‐Met. Associations between clinical variables present at the time of B‐Met diagnosis (eg, extracranial metastases, B‐Met location, and the presence of neurological symptoms) and post‐B–Met survival were also assessed. Univariate associations were analyzed using Kaplan‐Meier survival analysis, and the effect of independent predictors was assessed using multivariate Cox proportional hazards regression analysis. RESULTS: Of the 900 melanoma patients studied, 89 (10%) developed B‐Met. Ulceration and site of the primary tumor on the head and neck were found to be independent predictors of B‐Met development on multivariate analysis (P = .001 and P = .003, respectively). Clinical variables found to be predictive of post‐B–Met survival on multivariate analysis included the presence of neurological symptoms (P = .008) and extracranial metastases (P = .04). Ulceration was the only primary tumor characteristic that remained a significant predictor of post‐B–Met survival on multivariate analysis (P = .04). CONCLUSIONS: Primary tumor ulceration was found to be the strongest predictor of B‐Met development and remained an independent predictor of decreased post‐B–Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B‐Met can improve clinical outcome. Cancer 2011. © 2010 American Cancer Society. Ulceration of the primary tumor was found to be the strongest predictor of melanoma brain metastases (B‐Met) development and remained an independent predictor of decreased post‐B–Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B‐Met can improve clinical outcome.
AbstractList Melanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B-Met development and post-B-Met survival. A prospectively accrued cohort of 900 melanoma patients was studied to identify clinicopathologic features of primary melanoma (eg, thickness, ulceration, mitotic index, and lymphovascular invasion) that are predictive of B-Met development and survival after a diagnosis of B-Met. Associations between clinical variables present at the time of B-Met diagnosis (eg, extracranial metastases, B-Met location, and the presence of neurological symptoms) and post-B-Met survival were also assessed. Univariate associations were analyzed using Kaplan-Meier survival analysis, and the effect of independent predictors was assessed using multivariate Cox proportional hazards regression analysis. Of the 900 melanoma patients studied, 89 (10%) developed B-Met. Ulceration and site of the primary tumor on the head and neck were found to be independent predictors of B-Met development on multivariate analysis (P = .001 and P = .003, respectively). Clinical variables found to be predictive of post-B-Met survival on multivariate analysis included the presence of neurological symptoms (P = .008) and extracranial metastases (P = .04). Ulceration was the only primary tumor characteristic that remained a significant predictor of post-B-Met survival on multivariate analysis (P = .04). Primary tumor ulceration was found to be the strongest predictor of B-Met development and remained an independent predictor of decreased post-B-Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B-Met can improve clinical outcome.
BACKGROUND: Melanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B-Met development and post-B-Met survival. METHODS: A prospectively accrued cohort of 900 melanoma patients was studied to identify clinicopathologic features of primary melanoma (eg, thickness, ulceration, mitotic index, and lymphovascular invasion) that are predictive of B-Met development and survival after a diagnosis of B-Met. Associations between clinical variables present at the time of B-Met diagnosis (eg, extracranial metastases, B-Met location, and the presence of neurological symptoms) and post-B-Met survival were also assessed. Univariate associations were analyzed using Kaplan-Meier survival analysis, and the effect of independent predictors was assessed using multivariate Cox proportional hazards regression analysis. RESULTS: Of the 900 melanoma patients studied, 89 (10%) developed B-Met. Ulceration and site of the primary tumor on the head and neck were found to be independent predictors of B-Met development on multivariate analysis (P = .001 and P = .003, respectively). Clinical variables found to be predictive of post-B-Met survival on multivariate analysis included the presence of neurological symptoms (P = .008) and extracranial metastases (P = .04). Ulceration was the only primary tumor characteristic that remained a significant predictor of post-B-Met survival on multivariate analysis (P = .04). CONCLUSIONS: Primary tumor ulceration was found to be the strongest predictor of B-Met development and remained an independent predictor of decreased post-B-Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B-Met can improve clinical outcome. Cancer 2011. [copy 2010 American Cancer Society.
BACKGROUNDMelanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B-Met development and post-B-Met survival. METHODSA prospectively accrued cohort of 900 melanoma patients was studied to identify clinicopathologic features of primary melanoma (eg, thickness, ulceration, mitotic index, and lymphovascular invasion) that are predictive of B-Met development and survival after a diagnosis of B-Met. Associations between clinical variables present at the time of B-Met diagnosis (eg, extracranial metastases, B-Met location, and the presence of neurological symptoms) and post-B-Met survival were also assessed. Univariate associations were analyzed using Kaplan-Meier survival analysis, and the effect of independent predictors was assessed using multivariate Cox proportional hazards regression analysis. RESULTSOf the 900 melanoma patients studied, 89 (10%) developed B-Met. Ulceration and site of the primary tumor on the head and neck were found to be independent predictors of B-Met development on multivariate analysis (P = .001 and P = .003, respectively). Clinical variables found to be predictive of post-B-Met survival on multivariate analysis included the presence of neurological symptoms (P = .008) and extracranial metastases (P = .04). Ulceration was the only primary tumor characteristic that remained a significant predictor of post-B-Met survival on multivariate analysis (P = .04). CONCLUSIONSPrimary tumor ulceration was found to be the strongest predictor of B-Met development and remained an independent predictor of decreased post-B-Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B-Met can improve clinical outcome.
BACKGROUND: Melanoma patients who develop brain metastases (B‐Met) have limited survival and are excluded from most clinical trials. In the current study, the authors attempted to identify primary tumor characteristics and clinical features predictive of B‐Met development and post‐B–Met survival. METHODS: A prospectively accrued cohort of 900 melanoma patients was studied to identify clinicopathologic features of primary melanoma (eg, thickness, ulceration, mitotic index, and lymphovascular invasion) that are predictive of B‐Met development and survival after a diagnosis of B‐Met. Associations between clinical variables present at the time of B‐Met diagnosis (eg, extracranial metastases, B‐Met location, and the presence of neurological symptoms) and post‐B–Met survival were also assessed. Univariate associations were analyzed using Kaplan‐Meier survival analysis, and the effect of independent predictors was assessed using multivariate Cox proportional hazards regression analysis. RESULTS: Of the 900 melanoma patients studied, 89 (10%) developed B‐Met. Ulceration and site of the primary tumor on the head and neck were found to be independent predictors of B‐Met development on multivariate analysis (P = .001 and P = .003, respectively). Clinical variables found to be predictive of post‐B–Met survival on multivariate analysis included the presence of neurological symptoms (P = .008) and extracranial metastases (P = .04). Ulceration was the only primary tumor characteristic that remained a significant predictor of post‐B–Met survival on multivariate analysis (P = .04). CONCLUSIONS: Primary tumor ulceration was found to be the strongest predictor of B‐Met development and remained an independent predictor of decreased post‐B–Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B‐Met can improve clinical outcome. Cancer 2011. © 2010 American Cancer Society. Ulceration of the primary tumor was found to be the strongest predictor of melanoma brain metastases (B‐Met) development and remained an independent predictor of decreased post‐B–Met survival in a multivariate analysis inclusive of primary tumor characteristics and clinical variables. The results of the current study suggest that patients with ulcerated primary tumors should be prospectively studied to determine whether heightened surveillance for B‐Met can improve clinical outcome.
Author Hernando, Eva
Pavlick, Anna
Geraghty, Laurel N.
Rose, Amy E.
Mazumdar, Madhu
Osman, Iman
Darvishian, Farbod
Zakrzewski, Jan
Christos, Paul J.
Shapiro, Richard
Berman, Russell
Polsky, David
Author_xml – sequence: 1
  givenname: Jan
  surname: Zakrzewski
  fullname: Zakrzewski, Jan
– sequence: 2
  givenname: Laurel N.
  surname: Geraghty
  fullname: Geraghty, Laurel N.
– sequence: 3
  givenname: Amy E.
  surname: Rose
  fullname: Rose, Amy E.
– sequence: 4
  givenname: Paul J.
  surname: Christos
  fullname: Christos, Paul J.
– sequence: 5
  givenname: Madhu
  surname: Mazumdar
  fullname: Mazumdar, Madhu
– sequence: 6
  givenname: David
  surname: Polsky
  fullname: Polsky, David
– sequence: 7
  givenname: Richard
  surname: Shapiro
  fullname: Shapiro, Richard
– sequence: 8
  givenname: Russell
  surname: Berman
  fullname: Berman, Russell
– sequence: 9
  givenname: Farbod
  surname: Darvishian
  fullname: Darvishian, Farbod
– sequence: 10
  givenname: Eva
  surname: Hernando
  fullname: Hernando, Eva
– sequence: 11
  givenname: Anna
  surname: Pavlick
  fullname: Pavlick, Anna
– sequence: 12
  givenname: Iman
  surname: Osman
  fullname: Osman, Iman
  email: iman.osman@nyumc.org
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=24042181$$DView record in Pascal Francis
https://www.ncbi.nlm.nih.gov/pubmed/21472718$$D View this record in MEDLINE/PubMed
BookMark eNp9kc-KFDEQxoOsuLOrFx9AchFF6DVJpzuZ49L4DxYFUfDW1CQVNpJOj0l3y958hD3sE_okZnZm9SAspAiV-vFVpb4TchTHiIQ85eyMMyZem2jSmWhaWT8gK87WqmJciiOyYozpqpH1t2NykvP3kirR1I_IseBSCcX1itx0wUdvINAFkodNwEwhWrpNfoB0Rad5GBM1l5DATJh8nrzJpYrWm8kvSEdHp0ukFhcM43bAOO2eBgwQxwHoJoGPJZ0gl3MnPubp96_r_2p5TotfIDwmDx2EjE8O9yn5-vbNl-59dfHp3Yfu_KIyUqi6soq3zCmn19y6GtY1422tuGRSNgJBWuusc1YaqRGxlSgbZZwBobVaG9D1KXmx192m8ceMeeoHnw2GMjuOc-51ywWTTPNCvryX5KLWJQpc0Fd71KQx54SuP-yy56zf-dXv_Opv_Srws4PuvBnQ_kXvDCrA8wMAubjkEkTj8z-ufFbw2wH5nvvpA17d07LvPnaf983_AOKhs6Q
CODEN CANCAR
CitedBy_id crossref_primary_10_1038_s41598_019_40570_1
crossref_primary_10_1245_s10434_014_3829_9
crossref_primary_10_1007_s10585_013_9611_8
crossref_primary_10_1097_PPO_0b013e31824b2890
crossref_primary_10_3171_2014_9_JNS141425
crossref_primary_10_3390_biom10101357
crossref_primary_10_1002_cncr_30946
crossref_primary_10_1007_s12032_013_0466_2
crossref_primary_10_1093_noajnl_vdz017
crossref_primary_10_3390_cells11121873
crossref_primary_10_3390_cancers16112134
crossref_primary_10_1097_CMR_0b013e32835ae915
crossref_primary_10_4103_fjs_fjs_107_18
crossref_primary_10_2310_7750_2013_13045
crossref_primary_10_1038_s41582_020_0391_x
crossref_primary_10_1002_jso_23574
crossref_primary_10_1007_s11912_013_0335_3
crossref_primary_10_1080_08923973_2023_2215403
crossref_primary_10_1016_j_ejca_2021_07_028
crossref_primary_10_1016_j_rpor_2015_12_001
crossref_primary_10_1093_neuonc_nos113
crossref_primary_10_1155_2012_294735
crossref_primary_10_1002_cncr_34435
crossref_primary_10_2217_mmt_15_16
crossref_primary_10_1016_j_hoc_2024_05_008
crossref_primary_10_3390_app14062222
crossref_primary_10_1093_noajnl_vdab170
crossref_primary_10_3389_fonc_2021_554668
crossref_primary_10_1007_s40495_016_0072_z
crossref_primary_10_1007_s11060_016_2072_6
crossref_primary_10_1002_cam4_1223
crossref_primary_10_1007_s11912_011_0203_y
crossref_primary_10_1007_s40257_022_00678_z
crossref_primary_10_2478_raon_2022_0032
crossref_primary_10_1590_0101_60830000000118
crossref_primary_10_3389_fonc_2022_868004
crossref_primary_10_1016_j_clon_2013_07_002
crossref_primary_10_1007_s11095_018_2455_9
crossref_primary_10_3390_cancers15215263
crossref_primary_10_1097_CMR_0000000000000429
crossref_primary_10_1097_CMR_0b013e32834d3d88
crossref_primary_10_1016_j_ejca_2013_11_002
crossref_primary_10_1126_scitranslmed_ade8732
crossref_primary_10_1007_s11912_011_0200_1
crossref_primary_10_1007_s00761_013_2528_7
crossref_primary_10_1159_000461576
crossref_primary_10_3390_cancers12061635
crossref_primary_10_1016_j_clineuro_2013_03_019
crossref_primary_10_3390_cancers16122272
crossref_primary_10_1007_s00432_013_1553_7
crossref_primary_10_18632_oncotarget_19223
crossref_primary_10_3389_fonc_2022_824511
crossref_primary_10_3892_ijo_2015_2970
crossref_primary_10_1097_CMR_0000000000000338
crossref_primary_10_1111_cup_12746
crossref_primary_10_1111_pcmr_12771
crossref_primary_10_1186_s12885_015_1927_0
crossref_primary_10_1007_s12094_021_02607_8
crossref_primary_10_1097_CMR_0000000000000538
crossref_primary_10_1097_CMR_0b013e328352dbef
crossref_primary_10_1159_000519281
crossref_primary_10_1016_j_canrad_2014_11_001
crossref_primary_10_1097_CMR_0000000000000382
crossref_primary_10_1186_s12885_015_1517_1
crossref_primary_10_5301_jbm_5000089
Cites_doi 10.1159/000076903
10.1007/BF02071520
10.1056/NEJMra072149
10.1016/S0360-3016(96)00619-0
10.1097/CMR.0b013e3283090031
10.1038/nature08021
10.1002/cncr.22868
10.1158/0008-5472.CAN-08-0041
10.6004/jnccn.2009.0020
10.1002/cncr.22905
10.1038/nm.2072
10.1200/JCO.2006.08.1463
10.1159/000070289
10.1200/JCO.2009.23.4799
10.1200/JCO.1993.11.4.638
10.1215/15228517-2007-058
10.1200/JCO.2004.08.140
10.3171/jns.1998.88.1.0011
10.1158/1078-0432.CCR-07-4139
10.1097/01.pas.0000213262.61855.7d
ContentType Journal Article
Copyright Copyright © 2010 American Cancer Society
2015 INIST-CNRS
Copyright © 2010 American Cancer Society.
Copyright_xml – notice: Copyright © 2010 American Cancer Society
– notice: 2015 INIST-CNRS
– notice: Copyright © 2010 American Cancer Society.
DBID IQODW
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
7TK
7X8
DOI 10.1002/cncr.25643
DatabaseName Pascal-Francis
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Neurosciences Abstracts
MEDLINE - Academic
DatabaseTitleList MEDLINE
Neurosciences Abstracts
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: ECM
  name: MEDLINE
  url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1097-0142
EndPage 1720
ExternalDocumentID 10_1002_cncr_25643
21472718
24042181
CNCR25643
Genre article
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NCI NIH HHS
  grantid: 5 P30 CA 016087-27
– fundername: NCI NIH HHS
  grantid: P30 CA016087-28
– fundername: NCI NIH HHS
  grantid: P30 CA016087-29
– fundername: NCI NIH HHS
  grantid: P30 CA016087
GroupedDBID ---
-~X
.3N
.GA
.Y3
05W
0R~
10A
1CY
1L6
1OC
24P
29B
31~
33P
3SF
3WU
4.4
4ZD
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5GY
5VS
66C
6J9
6P2
6PF
702
7PT
8-0
8-1
8-3
8-4
8-5
85S
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AARRQ
AAWTL
AAXRX
AAZKR
ABCQN
ABCUV
ABEML
ABHFT
ABIJN
ABIVO
ABJNI
ABLJU
ABOCM
ABPPZ
ABPVW
ABQWH
ABXGK
ACAHQ
ACCZN
ACFBH
ACGFO
ACGFS
ACGOF
ACMXC
ACNCT
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
ADZOD
AEIGN
AEIMD
AENEX
AEUQT
AEUYR
AFBPY
AFFPM
AFGKR
AFPWT
AFRAH
AFZJQ
AGNAY
AHBTC
AIACR
AIAGR
AITYG
AIURR
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZVAB
BAFTC
BAWUL
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BY8
C45
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
E3Z
EBS
EJD
EX3
F00
F01
F04
F5P
FD6
FUBAC
G-S
G.N
GNP
GODZA
GX1
H.X
HBH
HF~
HGLYW
HHY
HHZ
HZ~
IH2
IX1
J0M
JPC
KBYEO
KQQ
KZ1
L7B
LATKE
LAW
LC2
LC3
LH4
LITHE
LMP
LOXES
LP6
LP7
LSO
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
NNB
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
Q.N
Q11
QB0
QRW
R.K
ROL
RWI
RX1
RYL
SJN
SUPJJ
TEORI
UDS
UHB
V2E
V8K
V9Y
W8V
W99
WBKPD
WH7
WHWMO
WIH
WIJ
WIK
WIN
WJL
WOHZO
WQJ
WRC
WVDHM
WXI
WXSBR
XG1
XPP
XV2
Z0Y
ZGI
ZZTAW
~IA
~WT
.GJ
08R
3O-
AAJUZ
AAUGY
AAVGM
ABCVL
ABHUG
ABPTK
ABWRO
ACCFJ
ACXME
ADAWD
ADDAD
AEEZP
AEQDE
AFFNX
AFVGU
AGJLS
AI.
AIWBW
AJBDE
AKALU
C1A
EMOBN
H~9
IQODW
J5H
N4W
NEJ
OHT
RSU
VH1
WHG
XFK
Y6R
YQJ
ZA5
ZXP
CGR
CUY
CVF
ECM
EIF
NPM
AAMNL
AAYXX
CITATION
7TK
7X8
ID FETCH-LOGICAL-c4273-d7160f7f891df3a93016371404452ea4ddfdffd4c48eee64e457cfca28879ca83
IEDL.DBID 33P
ISSN 0008-543X
1097-0142
IngestDate Fri Aug 16 07:55:19 EDT 2024
Fri Aug 16 23:58:09 EDT 2024
Thu Nov 21 21:20:36 EST 2024
Sat Sep 28 07:59:13 EDT 2024
Sun Oct 22 16:05:35 EDT 2023
Sat Aug 24 01:04:39 EDT 2024
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 8
Keywords Nervous system diseases
Prognosis
Brain cancer
Central nervous system
melanoma
Tumorigenicity
Malignant tumor
Cerebral metastasis
brain
Carcinogenesis
Survival
Cerebral disorder
Encephalon
metastases
Cancerology
outcomes
Central nervous system disease
Malignant melanoma
Primary
Ulceration
Cancer
Language English
License CC BY 4.0
Copyright © 2010 American Cancer Society.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c4273-d7160f7f891df3a93016371404452ea4ddfdffd4c48eee64e457cfca28879ca83
Notes Preliminary findings were presented at the Annual Meeting of the American Society of Clinical Oncology; May 29‐June 2, 2009; Orlando, FL.
See editorial and companion articles on pages 1560‐3, 1687‐96, and 1697‐703, this issue.
The first 2 authors contributed equally to this article.
Fax: (212) 263‐9090
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
OpenAccessLink https://onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.25643
PMID 21472718
PQID 1238123040
PQPubID 23462
PageCount 10
ParticipantIDs proquest_miscellaneous_861204081
proquest_miscellaneous_1238123040
crossref_primary_10_1002_cncr_25643
pubmed_primary_21472718
pascalfrancis_primary_24042181
wiley_primary_10_1002_cncr_25643_CNCR25643
PublicationCentury 2000
PublicationDate 15 April 2011
PublicationDateYYYYMMDD 2011-04-15
PublicationDate_xml – month: 04
  year: 2011
  text: 15 April 2011
  day: 15
PublicationDecade 2010
PublicationPlace Hoboken
PublicationPlace_xml – name: Hoboken
– name: Hoboken, NJ
– name: United States
PublicationTitle Cancer
PublicationTitleAlternate Cancer
PublicationYear 2011
Publisher Wiley Subscription Services, Inc., A Wiley Company
Wiley-Blackwell
Publisher_xml – name: Wiley Subscription Services, Inc., A Wiley Company
– name: Wiley-Blackwell
References 2004; 22
2006; 30
2010; 16
2004; 27
2008; 18
2008; 14
2008; 10
2004
1992; 16
2009; 459
2009; 27
1998; 88
2007; 357
1984; 53
2007; 215
1997; 37
2007; 110
1993; 11
2005; 52
2008; 68
2007; 60
2009; 7
2009; 1
2003; 64
2007; 25
18765540 - Clin Cancer Res. 2008 Sep 1;14(17):5484-93
17623835 - Cancer. 2007 Sep 15;110(6):1329-37
18046031 - N Engl J Med. 2007 Nov 29;357(22):2277-84
19966936 - Am J Transl Res. 2009;1(1):35-43
18626311 - Melanoma Res. 2008 Aug;18(4):268-73
19917835 - J Clin Oncol. 2009 Dec 20;27(36):6199-206
15800714 - Neoplasma. 2005;52(2):150-8
8478659 - J Clin Oncol. 1993 Apr;11(4):638-43
17369575 - J Clin Oncol. 2007 Mar 20;25(9):1129-34
19401060 - J Natl Compr Canc Netw. 2009 Mar;7(3):250-75
6713349 - Cancer. 1984 Jun 1;53(11):2550-2
15138346 - Onkologie. 2004 Apr;27(2):145-9
18559492 - Cancer Res. 2008 Jun 15;68(12):4500-5
15051777 - J Clin Oncol. 2004 Apr 1;22(7):1293-300
12759528 - Oncology. 2003;64(4):328-35
17620286 - Cancer. 2007 Sep 1;110(5):1107-14
9128946 - Int J Radiat Oncol Biol Phys. 1997 Mar 1;37(4):745-51
17063079 - Am J Surg Pathol. 2006 Nov;30(11):1396-400
19421193 - Nature. 2009 Jun 18;459(7249):1005-9
17587834 - Dermatology. 2007;215(1):10-6
18287337 - Neuro Oncol. 2008 Apr;10(2):199-207
20023634 - Nat Med. 2010 Jan;16(1):116-22
1561798 - World J Surg. 1992 Mar-Apr;16(2):191-5
21472703 - Cancer. 2011 Apr 15;117(8):1560-3
17327791 - Neurosurgery. 2007 Mar;60(3):471-81; discussion 481-2
9420067 - J Neurosurg. 1998 Jan;88(1):11-20
e_1_2_7_5_2
e_1_2_7_4_2
e_1_2_7_3_2
e_1_2_7_2_2
Mathieu D (e_1_2_7_22_2) 2007; 60
e_1_2_7_8_2
Eggermont AM (e_1_2_7_12_2) 2009; 27
e_1_2_7_7_2
e_1_2_7_18_2
Baurain J (e_1_2_7_13_2) 2009; 27
e_1_2_7_17_2
e_1_2_7_16_2
Madajewicz S (e_1_2_7_20_2) 1984; 53
e_1_2_7_15_2
e_1_2_7_11_2
e_1_2_7_10_2
Panagiotou IE (e_1_2_7_19_2) 2005; 52
e_1_2_7_26_2
e_1_2_7_27_2
e_1_2_7_28_2
e_1_2_7_29_2
Thompson JF (e_1_2_7_6_2) 2004
Hofmann MA (e_1_2_7_9_2) 2007; 215
e_1_2_7_25_2
Wich LG (e_1_2_7_14_2) 2009; 1
e_1_2_7_24_2
e_1_2_7_23_2
e_1_2_7_21_2
References_xml – volume: 53
  start-page: 2550
  year: 1984
  end-page: 2552
  article-title: Malignant melanoma brain metastases
  publication-title: Review of Roswell Park Memorial Institute experience. Cancer.
– volume: 110
  start-page: 1329
  year: 2007
  end-page: 1337
  article-title: Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases
  publication-title: Cancer.
– volume: 18
  start-page: 268
  year: 2008
  end-page: 273
  article-title: Serum matrix metalloproteinase‐8 is associated with ulceration and vascular invasion of malignant melanoma
  publication-title: Melanoma Res.
– volume: 68
  start-page: 4500
  year: 2008
  end-page: 4505
  article-title: Development of a preclinical model of spontaneous human melanoma central nervous system metastasis
  publication-title: Cancer Res.
– volume: 88
  start-page: 11
  year: 1998
  end-page: 20
  article-title: Demographics, prognosis, and therapy in 702 patients with brain metastases from malignant melanoma
  publication-title: J Neurosurg.
– volume: 27
  start-page: 145
  year: 2004
  end-page: 149
  article-title: Survival and prognostic factors in patients with brain metastases from malignant melanoma
  publication-title: Onkologie.
– volume: 27
  issue: 15 suppl
  year: 2009
  article-title: Association of primary melanoma ulceration and clinical benefit of adjuvant vaccination with tumor‐specific antigen peptides [abstract]
  publication-title: J Clin Oncol.
– volume: 25
  start-page: 1129
  year: 2007
  end-page: 1134
  article-title: Identification of high‐risk patients among those diagnosed with thin cutaneous melanomas
  publication-title: J Clin Oncol.
– volume: 64
  start-page: 328
  year: 2003
  end-page: 335
  article-title: Biochemotherapy for metastatic melanoma with limited central nervous system involvement
  publication-title: Oncology.
– volume: 52
  start-page: 150
  year: 2005
  end-page: 158
  article-title: Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome
  publication-title: Neoplasma.
– volume: 1
  start-page: 35
  year: 2009
  end-page: 43
  article-title: Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research
  publication-title: Am J Transl Res.
– volume: 27
  start-page: 6199
  year: 2009
  end-page: 6206
  article-title: Final version of 2009 AJCC melanoma staging and classification
  publication-title: J Clin Oncol.
– volume: 30
  start-page: 1396
  year: 2006
  end-page: 1400
  article-title: Prognostic significance of extent of ulceration in primary cutaneous melanoma
  publication-title: Am J Surg Pathol.
– volume: 16
  start-page: 191
  year: 1992
  end-page: 195
  article-title: Predicting survival and recurrence in localized melanoma: a multivariate approach
  publication-title: World J Surg.
– volume: 27
  issue: 15 suppl
  year: 2009
  publication-title: J Clin Oncol.
– volume: 11
  start-page: 638
  year: 1993
  end-page: 643
  article-title: Role of computed tomography in the staging of primary melanoma
  publication-title: J Clin Oncol.
– volume: 357
  start-page: 2277
  year: 2007
  end-page: 2284
  article-title: Computed tomography–an increasing source of radiation exposure
  publication-title: N Engl J Med.
– volume: 14
  start-page: 5484
  year: 2008
  end-page: 5493
  article-title: Effective CpG immunotherapy of breast carcinoma prevents but fails to eradicate established brain metastasis
  publication-title: Clin Cancer Res.
– volume: 37
  start-page: 745
  year: 1997
  end-page: 751
  article-title: Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials
  publication-title: Int J Radiat Oncol Biol Phys.
– volume: 110
  start-page: 1107
  year: 2007
  end-page: 1114
  article-title: Role of radiologic imaging at the time of initial diagnosis of stage T1b‐T3b melanoma
  publication-title: Cancer.
– year: 2004
– volume: 22
  start-page: 1293
  year: 2004
  end-page: 1300
  article-title: Determinants of outcome in melanoma patients with cerebral metastases
  publication-title: J Clin Oncol.
– volume: 60
  start-page: 471
  year: 2007
  end-page: 481
  article-title: et al
  publication-title: Gamma knife radiosurgery in the management of malignant melanoma brain metastases.
– volume: 7
  start-page: 250
  year: 2009
  end-page: 275
  article-title: Melanoma
  publication-title: J Natl Compr Canc Netw.
– volume: 16
  start-page: 116
  year: 2010
  end-page: 122
  article-title: Real‐time imaging reveals the single steps of brain metastasis formation
  publication-title: Nat Med.
– volume: 10
  start-page: 199
  year: 2008
  end-page: 207
  article-title: Brain and leptomeningeal metastases from cutaneous melanoma: survival outcomes based on clinical features
  publication-title: Neuro Oncol.
– volume: 215
  start-page: 10
  year: 2007
  end-page: 16
  article-title: et al
  publication-title: Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women? Dermatology.
– volume: 459
  start-page: 1005
  year: 2009
  end-page: 1009
  article-title: Genes that mediate breast cancer metastasis to the brain
  publication-title: Nature.
– volume: 215
  start-page: 10
  year: 2007
  ident: e_1_2_7_9_2
  article-title: et al
  publication-title: Prognostic factors and impact of treatment in melanoma brain metastases: better prognosis for women? Dermatology.
  contributor:
    fullname: Hofmann MA
– ident: e_1_2_7_4_2
  doi: 10.1159/000076903
– ident: e_1_2_7_17_2
  doi: 10.1007/BF02071520
– ident: e_1_2_7_27_2
  doi: 10.1056/NEJMra072149
– volume-title: Textbook of Melanoma
  year: 2004
  ident: e_1_2_7_6_2
  contributor:
    fullname: Thompson JF
– ident: e_1_2_7_5_2
  doi: 10.1016/S0360-3016(96)00619-0
– ident: e_1_2_7_15_2
  doi: 10.1097/CMR.0b013e3283090031
– volume: 27
  issue: 15
  year: 2009
  ident: e_1_2_7_13_2
  article-title: Association of primary melanoma ulceration and clinical benefit of adjuvant vaccination with tumor‐specific antigen peptides [abstract]
  publication-title: J Clin Oncol.
  contributor:
    fullname: Baurain J
– volume: 53
  start-page: 2550
  year: 1984
  ident: e_1_2_7_20_2
  article-title: Malignant melanoma brain metastases
  publication-title: Review of Roswell Park Memorial Institute experience. Cancer.
  contributor:
    fullname: Madajewicz S
– ident: e_1_2_7_18_2
  doi: 10.1038/nature08021
– ident: e_1_2_7_25_2
  doi: 10.1002/cncr.22868
– volume: 52
  start-page: 150
  year: 2005
  ident: e_1_2_7_19_2
  article-title: Cerebral metastases of malignant melanoma: contemporary treatment modalities and survival outcome
  publication-title: Neoplasma.
  contributor:
    fullname: Panagiotou IE
– ident: e_1_2_7_7_2
  doi: 10.1158/0008-5472.CAN-08-0041
– ident: e_1_2_7_24_2
  doi: 10.6004/jnccn.2009.0020
– ident: e_1_2_7_21_2
  doi: 10.1002/cncr.22905
– ident: e_1_2_7_28_2
  doi: 10.1038/nm.2072
– ident: e_1_2_7_11_2
  doi: 10.1200/JCO.2006.08.1463
– ident: e_1_2_7_23_2
  doi: 10.1159/000070289
– ident: e_1_2_7_10_2
  doi: 10.1200/JCO.2009.23.4799
– volume: 60
  start-page: 471
  year: 2007
  ident: e_1_2_7_22_2
  article-title: et al
  publication-title: Gamma knife radiosurgery in the management of malignant melanoma brain metastases.
  contributor:
    fullname: Mathieu D
– ident: e_1_2_7_26_2
  doi: 10.1200/JCO.1993.11.4.638
– ident: e_1_2_7_8_2
  doi: 10.1215/15228517-2007-058
– ident: e_1_2_7_3_2
  doi: 10.1200/JCO.2004.08.140
– ident: e_1_2_7_2_2
  doi: 10.3171/jns.1998.88.1.0011
– volume: 27
  issue: 15
  year: 2009
  ident: e_1_2_7_12_2
  publication-title: J Clin Oncol.
  contributor:
    fullname: Eggermont AM
– ident: e_1_2_7_29_2
  doi: 10.1158/1078-0432.CCR-07-4139
– volume: 1
  start-page: 35
  year: 2009
  ident: e_1_2_7_14_2
  article-title: Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research
  publication-title: Am J Transl Res.
  contributor:
    fullname: Wich LG
– ident: e_1_2_7_16_2
  doi: 10.1097/01.pas.0000213262.61855.7d
SSID ssj0007253
Score 2.3881578
Snippet BACKGROUND: Melanoma patients who develop brain metastases (B‐Met) have limited survival and are excluded from most clinical trials. In the current study, the...
Melanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the authors...
BACKGROUND: Melanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the...
BACKGROUNDMelanoma patients who develop brain metastases (B-Met) have limited survival and are excluded from most clinical trials. In the current study, the...
SourceID proquest
crossref
pubmed
pascalfrancis
wiley
SourceType Aggregation Database
Index Database
Publisher
StartPage 1711
SubjectTerms Age Factors
Aged
Biological and medical sciences
Brain
Brain Neoplasms - mortality
Brain Neoplasms - pathology
Brain Neoplasms - secondary
Cancer
Clinical trials
Dermatology
Female
Head and neck
Humans
Male
Medical sciences
Melanoma
Melanoma - mortality
Melanoma - pathology
Melanoma - secondary
Metastases
Middle Aged
Multivariate analysis
outcomes
Prognosis
Regression analysis
Skin Neoplasms - pathology
Survival
Survival Analysis
Tumors
Tumors of the skin and soft tissue. Premalignant lesions
ulceration
Title Clinical variables and primary tumor characteristics predictive of the development of melanoma brain metastases and post‐brain metastases survival
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fcncr.25643
https://www.ncbi.nlm.nih.gov/pubmed/21472718
https://search.proquest.com/docview/1238123040
https://search.proquest.com/docview/861204081
Volume 117
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1La9wwEB7aHEqhJH3XTRNU2lPBjR-jtQy5hE1CLw2lD8jNyHqcsnZYr3PuT-ghvzC_pDOyd5elaSH0ZluyLDSvbyTrE8B7LAudqJrSEo0uRiyyWEufxxSsmPtDok7CIbbfirNzdXzCNDmHy70wAz_EasKNLSP4azZwXXcHa9JQ05j5RwrYyFSflCaE_Rv5l5UbLrKRgjJRscT8fMVNmh2sX92IRo8udUcD44cTLW6DnJsINoSg053_6_xj2B6hpzgadOUJ3HPNU3jweVxcfwbXI0fohbiiBJq3VHVCN1ZcDoQUYtHP2rkwmwzPVMoNsNMUrRcEJ4Vd_4fEj2buQjftTIuaT6Og24UmRNotG2-7xc3PX3-UdT35MLKC5_Dj9OT79FM8HtoQGyQoFFtKwBJfeFWm1ue6ZJEHVkBEmTmN1nrrvUWDyjk3QYeyMN7ojLxdabTKX8BW0zbuFQjJRDJuoimIavTGqrrMbOkmRVorlNJF8G4pvGocimpgYc4qHuAqDHAE-xtyXVUlLIMMcCJ4uxR0RbbFCya6cW3fVSnjGZ41TyIQf6mjCCJSBW7m5aAk6w-kpPoU-yP4EHThH52spmfTr-Hq9V0q78LDYY4b41S-ga3FvHd7cL-z_X4wht87BQ-m
link.rule.ids 315,782,786,1408,27933,27934,46064,46488
linkProvider Wiley-Blackwell
linkToHtml http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Jb9QwFH6iRYJKFWuXsBQjOCGlzfI8cQ4c0NCqiHaEoEi9RR4vp05STSY99yf00F_IL-G9JDOjEYuEuCWx41h-2-fn-DPAW8wzHakxTUs0uhAxS0ItfRpSsGLuD4k6ag-x_ZaNztXHQ6bJeT_fC9PxQywSbmwZrb9mA-eE9MGSNdSUZrpPERvTNbiLA9JE3sGRflk44izpSSgjFUpMzxfspMnB8t2VeLR5qWsaGt-dafE70LmKYdsgdPTwP7v_CB706FN86NTlMdxx5RO4d9qvrz-F254m9EJc0Ryad1XVQpdWXHacFGLWTKqpMKskz1TKDbDfFJUXhCiFXf6KxI8m7kKX1USLMR9IQbczTaC0njde1bMf1ze_lNUNuTEyhC34fnR4NjwO-3MbQoOEhkJLc7DIZ17lsfWpzlnqLTEgokycRmu99d6iQeWcG6BDmRlvdEIOLzdapduwXlal2wUhmUvGDTTFUY3eWDXOE5u7QRaPFUrpAngzl17RD0XRETEnBQ9w0Q5wAHsrgl1UJTiDjHECeD2XdEHmxWsmunRVUxcxQxpOnEcBiD_UUYQSqQI3s9NpyfIDMWk_hf8A3rXK8JdOFsPR8Gt79exfKr-C-8dnpyfFyafR5-ew0aW8MYzlC1ifTRv3EtZq2-y1lvETQtETzg
linkToPdf http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB7RIlWVEI-2QHgUV3CqlDaP8caRuKBtVyBgVQGVeou8fpy6yWqz4cxP4MAv5Jcwk2R3tQIqIW5JPHGsGc_MZzv-DPAK80xHakLDEo0uRMySUEufhpSsmPtDoo7aQ2w_Z-MrdXbONDmvl3thOn6I1YQbe0Ybr9nBZ9afrklDTWnmJ5SwMd2C20g4nJnz0_RiFYezpOegjFQoMb1akZMmp-t3N9LRnZmuSTO-O9LiT5hzE8K2OWh07_9afx_u9thTvOk6ywO45co92PnYr67vw4-eJPRafKURNO-pqoUurZh1jBRi0UyruTCbFM9UyhVw1BSVF4QnhV3_iMSPpu5al9VUiwkfR0G3C02QtF5WXtWLn9--_1ZWNxTEyA0O4HJ0_mX4NuxPbQgNEhYKLY3AIp95lcfWpzpnm7e0gIgycRqt9dZ7iwaVc26ADmVmvNEJhbvcaJU-hO2yKt1jEJKZZNxAUxbV6I1VkzyxuRtk8UShlC6Al0vjFb0qio6GOSlYwUWr4AAON-y6EiUwg4xwAjhaGrog5-IVE126qqmLmAENT5tHAYi_yCjCiCTA1TzqOsn6AzH1fUr-ARy3feGGRhbD8fBTe_XkX4RfwM7F2aj48G78_insdvPdGMbyGWwv5o17Dlu1bQ5bv_gF58oSdA
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Clinical+variables+and+primary+tumor+characteristics+predictive+of+the+development+of+melanoma+brain+metastases+and+post%E2%80%90brain+metastases+survival&rft.jtitle=Cancer&rft.au=Zakrzewski%2C+Jan&rft.au=Geraghty%2C+Laurel+N.&rft.au=Rose%2C+Amy+E.&rft.au=Christos%2C+Paul+J.&rft.date=2011-04-15&rft.pub=Wiley+Subscription+Services%2C+Inc.%2C+A+Wiley+Company&rft.issn=0008-543X&rft.eissn=1097-0142&rft.volume=117&rft.issue=8&rft.spage=1711&rft.epage=1720&rft_id=info:doi/10.1002%2Fcncr.25643&rft.externalDBID=10.1002%252Fcncr.25643&rft.externalDocID=CNCR25643
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0008-543X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0008-543X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0008-543X&client=summon